Document is current
Any future updates will be listed below
-
Authors
Tsutsui, Yusuke
Masui, Atsushi
Konishi, Satoshi https://orcid.org/0000-0002-3265-7491
Tsujimura, Taro
Iwasaki, Mio
Yamamoto, Takuya https://orcid.org/0000-0002-0022-3947
Gotoh, Shimpei https://orcid.org/0000-0002-8563-8200
-
Funding
Funding for this research was provided by:
Kyoto University (the iPS Cell Research Fund for CiRA)
Japan Agency for Medical Research and Development (JP23bm1323001)
Japan Agency for Medical Research and Development (JP23bm1423004)
Japan Agency for Medical Research and Development (JP25bk0104190)
Japan Agency for Medical Research and Development (JP24gm1910009)
Collaboration Research Fund to Kyoto University from Kyorin Pharmaceutical Co. Ltd. and the iPS Cell Research Fund for CiRA at Kyoto University
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 8 January 2026
First Online: 12 February 2026
Competing interests
: Y.T. and A.M. are employees and shareholders of Kyorin Pharmaceutical Co., Ltd. S.G. is a founder and shareholder of HiLung. M.I. is a scientific adviser for xFOREST Therapeutics without a salary, and all other authors declare no competing interests. S.G. filed the patents related to the methods of generating iPSC-derived lung cells in this study: WO2014168264A1, WO2016143803A1, and WO2016148307A1.
